|Status: In progress|
Treatment of PAH in adolescents and children (aged 8 to less than 18 years) of WHO Functional Class (FC) II to III including use in combination treatment. Efficacy has been shown in IPAH, familial, corrected congenital and in PAH associated with connective tissue disease.
|Medicine name||ambrisentan (Volibris®)|
|Formulation||2.5 mg, 5 mg, 10 mg film-coated tablet|
|BNF chapter||Cardiovascular system|
|Submission type||Licence extension for paediatric use|
|AWMSG meeting date||18/10/2022|
|Date of issue||TBC|